461701-10-0

Upstream product

• 34658-66-7 2-(4-bromophenyl)imidazo[1,2-a]pyridine 
• 73183-34-3 bis(pinacol)diborane 

Downstream Products

• 942589-82-4 methyl 5-(4-imidazo[1,2-a]pyridin-2-ylphenyl)-3-[(1-methylethyl)amino]-2-thiophenecarboxylate 
• 942589-52-8 methyl 5-(4-imidazo[1,2-a]pyridin-2-ylphenyl)-3-[[(trans-4-methylcyclohexyl)carbonyl](1-methylethyl)amino]-2-thiophenecarboxylate 
• 1243139-03-8 5-thiazolecarboxylic methyl ester 4-N-[(2,4-dimethyl-phenyl)-phosphonamidate methyl ester]-2-[phenyl-8aH-imidazori,2-alpyridine] 
• 330791-10-1 cis-N₂-(4-{4-amino-1-[4-(4-methylpiperazino)cyclohexyl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl}-2-fluorophenyl)-1,3-benzoxazol-2-amine 

Relevant academic research and scientific papers

Constructing Highly Efficient Blue OLEDs with External Quantum Efficiencies up to 7.5 % Based on Anthracene Derivatives

Acquiring desirable device performance with deep-blue color purity that fulfills practical application requirements is still a challenge. Bipolar fluorescent emitters with hybrid local and charge transfer (HLCT) state may serve to address this issue. Here

Heterocyclic arylamine compound and application thereof on organic electronic devices

The invention relates to the technical field of organic electroluminescence, in particular to a heterocyclic arylamine compound and application of the heterocyclic arylamine compound on electronic devices, especially applications of the heterocyclic aryla

2-CARBOXY THIOPHENE DERIVATIVES AS ANTI-VIRAL AGENTS

Anti-viral agents of compounds of Formula (I) wherein A, R1, R2 and R3 are as defined in the specification, processes for their preparation and their use in HCV treatment are provided.

ANTIVIRAL 2-CARBOXY-THIOPHENE COMPOUNDS

Anti-viral agents of compounds of Formula (I) : wherein A, R1, R2 and R3 are as defined in the specification, processes for their preparation and their use in HCV treatment are provided.

DERIVATIVES OF THIOPHENE CARBOXILIC ACID AS ANTIVIRAL AGENT

Anti-viral agents of compounds of Formuta (I) : wherein A, R1, R2 and R3 are as defined in the specification, processes for their preparation and their use in HCV treatment are provided.

Pyrazolopyrimidines as therapeutic agents

The present invention is directed to pyrazolopyrimidine derivatives of formula (I) wherein the substituents are defined herein, which are useful as kinase inhibitors and as such are useful for affecting angiogenesis and diseases and conditions associated with angiogenesis.

Pyrazolopyrimidines as therapeutic agents

The present invention provides compounds of Formula I, including pharmaceutically acceptable salts and/or prodrugs thereof, where G, Ra, R2, and R3 are defined as described herein.

Pyrazolopyrimidines as therapeutic agents

The present invention provides compounds of Formula I, including pharmaceutically acceptable salts and/or prodrugs thereof, where G, R2, and R3 are defined as described herein.